Related Experiment Videos
Iatrogenic Kaposi's sarcoma and HCV infection
M Monti1, L L Mancini, R Ceriani
1Departement of Dermatology, I.C. Humanitas, University of Milan, Via Manzoni, 56 - Rozzano (Milano), Italy. marcello.monti@humanitas.it
Summary
Iatrogenic Kaposi's sarcoma can develop rapidly in immunosuppressed patients, particularly when co-infected with both Human Herpesvirus 8 (HHV8) and Hepatitis C Virus (HCV). This case highlights a synergistic viral interaction potentially accelerating sarcoma development.
Area of Science:
- Immunology
- Oncology
- Virology
Background:
- Iatrogenic Kaposi's sarcoma (KS) is associated with immunosuppressive therapy and Human Herpesvirus 8 (HHV8) activation.
- KS typically manifests over a year after initiating immunosuppressive drugs.
- HHV8 positivity is common, even in healthy individuals, suggesting co-factors are crucial for KS development.
Observation:
- A 49-year-old woman, positive for both HHV8 and Hepatitis C Virus (HCV), developed Kaposi's sarcoma.
- The patient received a low dose of steroid therapy (methylprednisolone 16 mg/day).
- KS manifested after 9 months, a shorter period than average, and presented acutely with extensive skin lesions.
Findings:
- The rapid onset and extensive nature of KS were not fully explained by HHV8 positivity and low-dose steroid therapy alone.
- Both HHV8 and HCV produce proteins like IL-6 and IL-8, which can influence cell growth.
- A synergistic effect between HHV8 and HCV is hypothesized to contribute to the accelerated KS development.
Implications:
- This case suggests that co-infection with HHV8 and HCV may create a synergistic environment promoting rapid iatrogenic Kaposi's sarcoma.
- Further research is needed to understand the interplay of viral co-infections and immunosuppression in KS pathogenesis.
- Clinical monitoring for KS may need to consider viral status in patients on immunosuppressive therapy.